35 results about "Absorption drugs" patented technology

A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

Solid dosage forms are produced by absorbing solutions of drug:cyclodextrin inclusion complexes on absorbing matrices and then drying. The matrices may, but need not, disintegrate in water. The resulting forms are suitable for oral or sublingual administration, and also can be used in topical administrations to mucosa covered tissues. They are particularly suitable for sublingual administration because the eluted, nondisintegrated matrix (e.g., absorbing paper) can be recovered and checked for completion of elution. This enables documentation that effective absorption occurred from the mouth cavity.

The invention provides an administration combination and a preparation method and a use method thereof. The administration combination comprises treatment components carrying effective doses, absorbefacient, medical auxiliary materials, and solid preparation of a bioadhesive layer containing bioadhesive polymer, and further comprises a selectable impervious or semi-permeable coating layer which ensures that the treatment components and the absorbefacient have unidirectional release capability. A unidirectional release channel with unidirectional release capability is formed through manual or laser ablation technology, and the releasing rates of the treatment components and the absorbefacient in the solid preparation are nearly the same. The invention simultaneously provides the preparation and the use methods of the administration combination. Low-dose solid preparation prepared through a non-solvent granulation process can maintain the uniformity and the stability of the treatment components. The administration combination can promote the absorption of drug difficult to be absorbed, improves the bioavailability, adjusts the pharmacodynamic feature and improves the absorption efficiency of drug, has a low price, and is relatively easy to produce.

The invention belongs to the technical field of traditional Chinese pharmacology, and discloses a preparation method and a use of a sublingual administration preparation containing alkaloids extracted from lotus leaf or lotus plumule. The sublingual administration preparation can be rapidly absorbed by sublingual mucous membrane, directly enters blood, avoids first pass effect of livers, is convenient to take, and has reduced untoward effects and improved the curative effect.

The present invention discloses oral disintegrated difenidol hydrochloride tablet prepared through freeze- drying process and its preparation process. The oral disintegrated difenidol hydrochloride tablet has difenidol hydrochloride as main medicine component, solid dispersing carrier, disintegrant, effervescent agent, taste masking agent, excipient, etc. and features the freeze- drying preparing process. It may be disintegrated in oral cavity into particles smaller than 250 microns within 30 sec without need of water, and is especially suitable for patient with dysphagia. It has fast leaching out and absorption, fast acting and high bioavailability.

The invention relates to a radiopaque polyvinyl alcohol microsphere and a preparation method thereof, wherein the radiopaque polyvinyl alcohol microsphere comprises a polyvinyl alcohol hydrogel bead,2, 3, 5-triiodobenzaldehyde and organic acids. The radiopaque polyvinyl alcohol microspheres prepared by the invention have the advantages of short synthesis time, fast absorption rate of drugs and the like.

The invention provides a ticagrelor pharmaceutical composition. The composition comprises ticagrelor and a pharmaceutically acceptable carrier, wherein the weight percentage of the ticagrelor is 10%-20%, the pharmaceutically acceptable carrier is selected from any one or a combination of an adhesive, a disintegrating agent, a diluent, a lubricant and a glidant, and the weight percentage of the disintegrating agent is 10%-30%. By scientifically screening and optimizing the formula of a solid pharmaceutical composition, the dynamic disintegration time and the static disintegration time of tablets are remarkably shortened, a patient can quickly absorb a medicine conveniently, intubation is avoided, a clinical medication scheme is simplified, in addition, medication of a patient with dysphagia is facilitated, the medication compliance of the patient is remarkably improved, the particle size and the particle powder property of the ticagrelor are optimized, the problems of large tablet weight difference and poor content uniformity after tabletting caused by poor flowability of the ticagrelor are solved, the uniformity, effectiveness and safety of the medicine are improved, and the quality of the medicine is controllable.

The invention provides an externally-used traditional Chinese medicine composition for treating migraine. According to the composition, ligusticum wallichii is taken as a monarch drug in a prescription; fructus viticis, radix angelicae and notopterygium root for dispelling wind and relieving pain are taken as ministerial drugs; rhizoma corydalis is used for assisting in the monarch drug, the ministerial drugs are used for relieving pain, radix achyranthis bidentatae is used for ensuring proper downward flow of blood, and all the drugs are taken adjuvant drugs; and platycodon grandiflorum is taken a conductant drug. The drugs are combined for clearing upward flow and reducing downward flow, clearing heat in head, bringing illness out and rising qi while reducing heat so as to achieve the effects of dispersing blood stasis, dispelling wind and relieving pain. The drugs can be coordinated by honey. The traditional Chinese medicine composition is applied to acupoints of Yifeng, Geshu, Fengshi, Yongquan and Taichong on the two sides of a human body. The traditional Chinese medicine composition is reasonable in combination, and can be used for fulfilling the effects of dispersing blood stasis, relaxing bowels, dispelling wind and relieving pain in a comprehensive manner. Modern researches show that when the traditional Chinese medicine composition is applied to the corresponding acupoints, the traditional Chinese medicine composition can be better absorbed through the specific parts, the acupoints can be stimulated, meridian qi of main and collateral channels can be excited, the dual functions of the composition and the main and collateral channels can be brought into play, and thus the aim of preventing and treating diseases can be achieved. The total effective rate of the externally-used traditional Chinese medicine composition is up to 89.8%.

The invention discloses a method for separating and preparing pyrrole butyric acid self-emulsion from radix ranunculi ternati and the application of the pyrrole butyric acid self-emulsion. In the method, smashed particles of the radix ranunculi ternati herb or radix ranunculi ternati decoction pieces serve as raw material and are concentrated, extracted and washed to obtain the effective constituent pyrrole butyric acid, and then the pyrrole butyric acid self-emulsion is prepared. According to the method, the effective constituent pyrrole butyric acid can be efficiently extracted, and the radix ranunculi ternati serving as the natural raw material has the advantages of being easy to obtain and low in cost. Serving as a good carrier for drugs which are hard to dissolve and absorb, the pyrrole butyric acid self-emulsion prepared through the method can greatly increase the oral bioavailability of the drugs; a drug delivery system of the pyrrole butyric acid self-emulsion is easy to prepare and stable in nature and is a good carrier for improving the absorbability of the drugs which are hard to dissolve; as is proven in experimental verification, the pyrrole butyric acid self-emulsion prepared through the method has an excellent tubercle bacillus inhibiting effect.

Described herein are systems and methods for delivering an active agent to a target tissue of the ear, nose, or throat using a drug delivery platform having a therapeutic drug embedded as part of the drug delivery platform. The drug delivery platform is implanted in a target tissue, and the active agent is eluted from the body of the drug delivery platform for a target period of time, thereby delivering a therapeutic dose of the drug for the period of time. The duration of therapy of the implant into sinus tissue may be 3 to 12 months or longer, thereby providing an entire duration of alleviation for the duration of the allergy season. Furthermore, the duration of the therapy provides remission to an individual suffering from a symptom of a chronic paranasal sinus condition for a longer period of time than currently available therapies, thus allowing the therapy to be administered only every half a year or year.

The invention relates to the technical field of medicines, in particular to an enzalutamide soft capsule quick-release preparation and a preparation method thereof. The enzalutamide soft capsule quick-release preparation is composed of a capsule shell and a content, wherein the content is a suspension containing enzalutamide. The enzalutamide soft capsule quick-release preparation is composed of the following raw materials in parts by weight of 40 parts of enzalutamide, 40-60 parts of medium chain triglyceride, 50-100 parts of a thickening agent, and 0.3-5 parts of a flow aid. According to theenzalutamide soft capsule quick-release preparation disclosed by the invention, aiming at the property characteristics of enzalutamide medicines, a soft capsule is prepared by adopting a suspension system, so that the dispersion and absorption of the enzalutamide are promoted, the chemical and physical stability of the medicines is good, the dissolution of effective components is quick, and the bioavailability is high. The invention also provides the preparation method of the enzalutamide soft capsule quick-release preparation.

The invention discloses an online judgment method for an absorption end point of a typical modified double-base propellant absorption drug. The method comprises the following steps of firstly, respectively collecting NC with different concentrations and near infrared spectrums of high-energy explosives, determining typical characteristic peaks, and selecting a characteristic wave band as a basis for calculating the standard deviation of a moving window; then setting a workflow of repeated sampling in the absorption process; then simulating an absorption process, and carrying out real-time and online acquisition on the mixing condition of the absorption process; and finally, at different mixing time points, selecting n continuous spectrums each time for calculation, calculating real-time difference and standard deviation between the whole process and near infrared spectrums of characteristic peaks of main components through an MBSD algorithm, and judging an absorption end point. The method is advantaged in that by selecting the near infrared spectrum characteristic peaks of the components of the absorption medicine and prolonging the duration time of the mixing process, the mixing uniformity change condition of the absorption process is comprehensively reflected, an absorption end point is accurately judged, and a comprehensive and reasonable basis is provided for actual production of the absorption medicine.

The invention discloses an application of a capric acid-modified dendritic macromolecular derivative, in particular an application of a capric acid-modified dendritic macromolecular derivative G2-CA6as an absorption promoter. Through a mucosal absorption experiment, an applicant finds that the capric acid-modified dendritic macromolecular derivative G2-CA6 can effectively improve mucosal absorption of difficult-to-absorb drugs as the absorption promoter and has relatively low mucosal toxicity.